Virpax Pharmaceuticals, Inc.

As Stephen Rosen , head of the corporate practice in London at law firm Cooley observed, “We start 2022 in the rare position of the sector never having as high a profile amongst investors [as] it d

The market for initial public offerings in the US was vastly different in the first quarter of 2020 than it was during the same period of 2021. Uncertainty related to COVID-19 shut down global financi

A panel of drug developers, investors and advisors discussed the merits of going public in the US through an initial public offering or through a merger with a special purpose acquisition corporation